Liposomal Paclitaxel and Albumin-bound Paclitaxel (Nanovehicle Agents) for Gastric Cancer

Abstract

Gastric cancer has the third-highest cancer-related mortality rate. Paclitaxel is a microtubule stabilizer whose systemic chemotherapy regimen is widely used in clinical practice due to its major role in the chemotherapy of advanced gastric cancer. Nanovehicles are various nanoparticles with dissolved or dispersed drugs that are currently used clinically, such as nanoparticles, liposomes, and polymeric micelles. The common nanovehicle paclitaxel formulations, such as liposomal paclitaxel and albumin-bound paclitaxel, are remarkably effective in improving biocompatibility, reducing allergic reactions, and targeting and localizing drug release. Numerous studies have indicated better anticancer activity and tolerable toxicity of nanocarrier paclitaxel compared with solvent-based paclitaxel in gastric cancer, which constitutes a trendy direction in gastric cancer treatment research. This article reviews the preparation and clinical application of paclitaxel delivery by nanovehicles in gastric cancer to provide a reference for chemotherapy in patients with advanced gastric cancer.